Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome.
Komrokji RS, Carraway HE, Germing U, Wermke M, Zeidan AM, Fu E, Rüter B, Burkard U, Osswald A, Foran JM. Komrokji RS, et al. Among authors: osswald a. Haematologica. 2022 Nov 1;107(11):2742-2747. doi: 10.3324/haematol.2021.280500. Haematologica. 2022. PMID: 35734924 Free PMC article. Clinical Trial. No abstract available.
An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia.
Fiedler W, Montesinos P, Schliemann C, Middeke J, Vasu S, Scholz CW, Esteve J, Mondal S, Rüter B, Burkard U, Osswald A, Blum W. Fiedler W, et al. Among authors: osswald a. Haematologica. 2022 Dec 1;107(12):2977-2982. doi: 10.3324/haematol.2022.281128. Haematologica. 2022. PMID: 36005556 Free PMC article. Clinical Trial. No abstract available.
A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia.
Vasu S, Altman JK, Uy GL, Tallman MS, Gojo I, Lozanski G, Burkard U, Osswald A, James P, Rüter B, Blum W. Vasu S, et al. Among authors: osswald a. Haematologica. 2022 Mar 1;107(3):770-773. doi: 10.3324/haematol.2020.274118. Haematologica. 2022. PMID: 34854276 Free PMC article. Clinical Trial. No abstract available.
Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery.
Stock K, Estrada MF, Vidic S, Gjerde K, Rudisch A, Santo VE, Barbier M, Blom S, Arundkar SC, Selvam I, Osswald A, Stein Y, Gruenewald S, Brito C, van Weerden W, Rotter V, Boghaert E, Oren M, Sommergruber W, Chong Y, de Hoogt R, Graeser R. Stock K, et al. Among authors: osswald a. Sci Rep. 2016 Jul 1;6:28951. doi: 10.1038/srep28951. Sci Rep. 2016. PMID: 27364600 Free PMC article.
PREDECT Protocols for Complex 2D/3D Cultures.
Vidic S, Estrada MF, Gjerde K, Santo VE, Osswald A, Barbier M, Chong YT, Sommergruber W, de Hoogt R, Brito C, Graeser R. Vidic S, et al. Among authors: osswald a. Methods Mol Biol. 2019;1888:1-20. doi: 10.1007/978-1-4939-8891-4_1. Methods Mol Biol. 2019. PMID: 30519938
Protocols and characterization data for 2D, 3D, and slice-based tumor models from the PREDECT project.
de Hoogt R, Estrada MF, Vidic S, Davies EJ, Osswald A, Barbier M, Santo VE, Gjerde K, van Zoggel HJAA, Blom S, Dong M, Närhi K, Boghaert E, Brito C, Chong Y, Sommergruber W, van der Kuip H, van Weerden WM, Verschuren EW, Hickman J, Graeser R. de Hoogt R, et al. Among authors: osswald a. Sci Data. 2017 Nov 21;4:170170. doi: 10.1038/sdata.2017.170. Sci Data. 2017. PMID: 29160867 Free PMC article.
77 results